logo
Science Portal
Copyright © Médecins Sans Frontières
v2.1.5758.produseast1
About MSF Science Portal
About
Contact Us
Frequently Asked Questions (FAQs)
Privacy Policy
Terms of Use
Export All Citations
Copyright © Médecins Sans Frontières
v2.1.5758.produseast1
Showing 1 - 8 of 8 Items
Showing 1 - 8 of 8 Items
Citations
  • Download citations in various formats (CSV, BibTeX, EndNote) for use in reference managers and bibliographies.
  • Current Page (8)
  • CSV
  • BibTeX
  • EndNote
  • All Results (8)
  • CSV
  • BibTeX
  • EndNote
Sort By: Relevance
  • Newest to oldest
  • Oldest to newest
  • Relevance
Journal Article
|
Review

The development of a global research agenda and individual participant data platform for visceral leishmaniasis: challenges and future opportunities

Singh-Phulgenda S, Dahal P, Maguire BJ, Alvar J, Alves F,  et al.
2025-12-02 • Parasites and Vectors
2025-12-02 • Parasites and Vectors

BACKGROUND

Visceral leishmaniasis (VL) is one of the neglected tropical diseases (NTDs) listed by the World Health Organization (WHO). The disease is currently ...

Journal Article
|
Research
Journal Article
|
Research
Journal Article
|
Protocol
Journal Article
|
Protocol
Journal Article
|
Research
Journal Article
|
Research
Journal Article
|
Research

Patient insights research exploring disease awareness, patient life experience, and current management of visceral leishmaniasis in Bihar, India

Sundar S, Alves F, Ritmeijer K, den Boer M, Forsyth C,  et al.
2025-02-25 • PLOS Neglected Tropical Diseases
2025-02-25 • PLOS Neglected Tropical Diseases

BACKGROUND

Visceral leishmaniasis (VL) is a vector-borne disease caused by Leishmania parasites and transmitted by sand fly bites, targeted for elimination in I...

A phase II, non-comparative randomised trial of two treatments involving liposomal amphotericin B and miltefosine for post-kala-azar dermal leishmaniasis in India and Bangladesh

Sundar S, Pandey K, Mondal D, Madhukar M, Kamal Topno R,  et al.
2024-06-20 • PLOS Neglected Tropical Diseases
2024-06-20 • PLOS Neglected Tropical Diseases
BACKGROUND
In Southeast Asia, treatment is recommended for all patients with post-kala-azar dermal leishmaniasis (PKDL). Adherence to the first-line regimen, twelve weeks of miltefos...

Haematological dynamics following treatment of visceral leishmaniasis: a protocol for systematic review and individual participant data (IPD) meta-analysis

Munir A, Dahal P, Kumar R, Singh-Phulgenda S, Siddiqui NA,  et al.
2023-12-14 • BMJ Open
2023-12-14 • BMJ Open
INTRODUCTION
Visceral leishmaniasis (VL) is a parasitic disease with an estimated 30,000 new cases occurring annually. Despite anaemia being a common haematological manifestation of ...

Host, parasite and drug determinants of clinical outcomes following treatment of visceral leishmaniasis: a protocol for individual participant data meta-analysis

Kumar R, Dahal P, Singh-Phulgenda S, Siddiqui NA, Munir A,  et al.
2023-10-28 • BMJ Open
2023-10-28 • BMJ Open
INTRODUCTION
Visceral leishmaniasis (VL) is a parasitic disease with an estimated 30 000 new cases occurring annually. There is an observed variation in the efficacy of the current f...

Treatment options for visceral leishmaniasis: a systematic review of clinical studies done in India, 1980-2004

Olliaro PL, Guerin PJ, Gerstl S, Haaskjold AA, Rottingen JA,  et al.
2005-12-01 • Lancet Infectious Diseases
2005-12-01 • Lancet Infectious Diseases
The state of Bihar in India carries the largest share of the world's burden of antimony-resistant visceral leishmaniasis. We analysed clinical studies done in Bihar with different treatm...

Male predominance in reported Visceral Leishmaniasis cases: Nature or nurture? A comparison of population-based with health facility-reported data

Cloots K, Burza S, Malaviya P, Hasker E, Kansal S,  et al.
2020-01-29 • PLOS Neglected Tropical Diseases
2020-01-29 • PLOS Neglected Tropical Diseases
BACKGROUND
Bangladesh, India, and Nepal aim for the elimination of Visceral Leishmaniasis (VL), a systemic parasitic infectious disease, as a public health problem by 2020. For decad...

Who Is a typical patient with visceral leishmaniasis? Characterizing the demographic and nutritional profile of patients in Brazil, East Africa, and South Asia

Harhay MO, Olliaro PL, Vaillant M, Chappuis F, Angeles Lima M,  et al.
2011-04-05 • American Journal of Tropical Medicine and Hygiene
2011-04-05 • American Journal of Tropical Medicine and Hygiene
Drug-dosing recommendations for visceral leishmaniasis (VL) treatment are based on the patients' weight or age. A current lack of demographic and anthropometric data on patients hinders ...